943325-38-0

Basic information

• Product Name: 2-[(2S)-2-Amino-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione
• Synonyms: 2-[(2S)-2-Amino-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione;(S)-2-(2-amino-3-(3-fluorophenyl)propyl)isoindoline-1,3-dione;(S)-2-(2-amino-3-(3-fluorophenyl)propyl)isoindoline-1,3-dione hydrochloride
• CAS NO: 943325-38-0
• Molecular Formula: C₁₇H₁₅FN₂O₂
• Molecular Weight: 298.3116032
• Mol File: 943325-38-0.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-[(2S)-2-Amino-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(2S)-2-Amino-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione(943325-38-0)
• EPA Substance Registry System: 2-[(2S)-2-Amino-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione(943325-38-0)

Safety Data

• Hazardous Substances Data: 943325-38-0(Hazardous Substances Data)

Usage

Structure

Isoindole-1,3(2H)-dione derivative
A core structure of the compound, which is a modified version of the isoindole-1,3-dione molecule.
3. Aminoethyl substituent at the 2-position
An amino group (-NH2) attached to an ethyl chain (-CH2-CH3) at the second position of the isoindole core, which influences the compound's reactivity and properties.
4. 3-Fluorophenyl group at the 3-position
A phenyl ring (a six-membered carbon ring with alternating single and double bonds) with a fluorine atom attached at the third position of the isoindole core, which affects the compound's electronic properties and interactions with other molecules.
5. Potential biological and pharmacological activities
The compound may have effects on biological systems and exhibit properties that can be used in the treatment or management of diseases or conditions.
6. Use in medical research and drug development
The compound may be studied and utilized in the creation of new medications or therapies, as well as in understanding the mechanisms of action of existing drugs.
7. Context-dependent characteristics, uses, and effects
The specific properties, applications, and effects of the compound may vary depending on the particular context in which it is being used, such as the target biological system or the specific disease being treated.

Upstream product

• 114873-01-7 N-Boc-3-fluoro-L-phenylalanine 
• 944470-56-8 tert-butyl [(1S)-1-(3-fluorobenzyl)-2-hydroxyethyl]carbamate 
• 1201923-48-9 1,1-dimethylethyl {(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}carbamate 

Downstream Products

• 1430058-57-3 2-[(2S)-2-(3-bromo-7-oxo-5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-3-(3-fluorophenyl)propyl]-1H-isoindole-1,3(2H)-dione 
• 1202632-51-6 2-(4-chloro-1-methyl-1H-pyrazol-5-yl)-N-{(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}-1,3-oxazole-5-carboxamide 
• 1202632-47-0 N-{(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}-2-(1-methyl-1H-pyrazol-5-yl)-1,3-oxazole-5-carboxamide 
• 1202632-44-7 2-(4-chloro-1-methyl-1H-pyrazol-5-yl)-N-{(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}-1,3-thiazole-5-carboxamide 
• 1202632-41-4 N-{(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}-2-(1-methyl-1H-pyrazol-5-yl)-1,3-thiazole-5-carboxamide 
• 1202636-79-0 5-chloro-1-(4-chloro-1-methyl-1H-pyrazol-5-yl)-N-{(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}-1H-pyrrole-3-carboxamide 
• 1202636-65-4 N-{(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}-1-(1-methyl-1H-pyrazol-5-yl)-1H-pyrrole-3-carboxamide 
• 1202636-71-2 5-chloro-N-{(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}-1-(1-methyl-1H-pyrazol-5-yl)-1H-pyrrole-3-carboxamide 
• 1202636-72-3 1-(4-chloro-1-methyl-1H-pyrazol-5-yl)-N-{(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}-1H-pyrrole-3-carboxamide 
• 1202248-06-3 N-{(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}-2-(1-methyl-1H-pyrazol-5-yl)-1,3-oxazole-4-carboxamide 
• 1202248-02-9 2-(4-chloro-1-methyl-1H-pyrazol-5-yl)-N-{(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}-1,3-thiazole-4-carboxamide 
• 1202247-98-0 N-{(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}-2-(1-methyl-1H-pyrazol-5-yl)-1,3-thiazole-4-carboxamide 
• 1047645-80-6 5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-N-{(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}-2-thiophenecarboxamide 
• 1047645-75-9 5-chloro-N-{(1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-[(3-fluorophenyl)methyl]ethyl}-4-(1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide 

Relevant articles and documents

AFURESERTIB: Protein kinase B (PKB) inhibitor Oncolytic

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway plays key roles in cellular proliferation and survival. Mutations and alterations in this signal transduction pathway have been described in a variety of solid and hematopoietic malignancies, which may contribute to perpetuation of the disease in a number of ways. Increasing interest in targeting particular facets of this signaling cascade has led to the development of a number of novel anticancer agents, including afuresertib (GSK-2110183), an orally bioavailable pan-inhibitor of the RAC-alpha serine/threonine protein kinase, also referred to as protein kinase B or proto-oncogene c-Akt. The present review summarizes the preclinical and pharmacological aspects of afuresertib and early clinical experience.